| Literature DB >> 26517086 |
Jian-Chun Li1, Na Zhu1, Jin-Xiu Zhu1, Wen-Jing Zhang1, Hong-Min Zhang1, Qing-Qing Wang1, Xiao-Xiang Wu1, Xiu Wang1, Jin Zhang1, Ji-Fu Hao2.
Abstract
BACKGROUND: The aim of this study was to optimize the preparation method for self-assembled glyceryl monoolein-based cubosomes containing paeonol and to characterize the properties of this transdermal delivery system to improve the drug penetration ability in the skin.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26517086 PMCID: PMC4632989 DOI: 10.12659/msm.894484
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Chemical structure of paeonol.
Figure 2Size distribution of paeonol cubosomes and blank cubosomes. Homogenization conditions: (A) 800 bar for 6 cycles; (B) 800 bar for 9 cycles; (C) 800 bar for 12 cycles; (D) 1200 bar for 9 cycles; (E) 800 bar for 9 cycles of blank cubosomes.
Results of particle size under different homogenization conditions.
| Cubosome dispersion | Mean ±SD | Polydispersity index (PDI) |
|---|---|---|
| 800 bar for 6 cycles | 85.18±4.91 | 0.19±0.04 |
| 800 bar for 9 cycles | 83.74±1.56 | 0.16±0.004 |
| 800 bar for 12 cycles | 82.45±1.12 | 0.15±0.03 |
| 1200 bar for 9 cycles | 84.33±2.44 | 0.14±0.02 |
| Blank cubosome | 96.02±2.05 | 0.15±0.01 |
Particle size and zeta potential of paeonol cubosomes and blank cubosomes.
| Sample | Average size (nm) | Zeta potential (mv) | PDI |
|---|---|---|---|
| Paeonol cubosome | 84.65±2.08 | −33.6±0.96 | 0.13±0.03 |
| Blank cubosome | 93.57±1.21 | −40.8±1.29 | 0.18±0.04 |
Figure 3Zeta potential distribution of paeonol cubosomes (A) and blank cubosomes (B).
Effects of paeonol content on particle size and zeta potential of the cuosomes (n=3).
| Paeonol (g) | Mean particle size (nm) | PDI | Zeta potential (mv) |
|---|---|---|---|
| 0.24 | 85.51±2.19 | 0.12±0.02 | −26.5±1.04 |
| 0.32 | 84.29±1.50 | 0.09±0.01 | −31.4±1.57 |
| 0.40 | 84.33±2.97 | 0.16±0.02 | −38.4±2.36 |
Effects of peaonol content on entrapment efficiency (n=3).
| Paeonol (g) | Entrapment efficiency (%) | Actual drug-loading (%) |
|---|---|---|
| 0.24 | 90.89±2.09 | 6% |
| 0.32 | 93.28±3.66 | 8% |
| 0.40 | 91.37±2.84 | 10% |
Figure 4Distribution and the shape of paeonol GMO-based cubosomes (A) and the inner structure of paeonol GMO-based cubosomes (B).
Figure 5PLM of paeonol GMO-based cubosomes.
Figure 6The DSC thermograms of Paeonol (A), GMO and P407 (B), physical mixture (C), paeonol cubosome (D).
The evaluation result of the complete skin group (n=4).
| Market ointment group | Cubosome group | ||||||
|---|---|---|---|---|---|---|---|
| Time | Score | Number | Result | Time | Score | Number | Result |
| 1 h | 1.25 | 4 | Mild irritation | 1 h | 0.25 | 1 | No irritation |
| 24 h | 0.25 | 1 | No irritation | 24 h | 0.25 | 1 | No irritation |
| 48 h | 0.25 | 1 | No irritation | 48 h | 0.00 | 0 | No irritation |
| 72 h | 0.00 | 0 | No irritation | 72 h | 0.00 | 0 | No irritation |
The evaluation result of the damaged skin group (n=4).
| Market ointment group | Cubosome group | ||||||
|---|---|---|---|---|---|---|---|
| Time | Score | Number | Result | Time | Score | Number | Result |
| 1 h | 2.00 | 4 | Mild irritation | 1 h | 1.25 | 3 | Mild irritation |
| 24 h | 1.00 | 3 | Mild irritation | 24 h | 0.25 | 1 | No irritation |
| 48 h | 0.25 | 1 | No irritation | 48 h | 0.00 | 0 | No irritation |
| 72 h | 0.0 | 0 | No irritation | 72 h | 0.00 | 0 | No irritation |
Figure 7The figures of pathological skin irritation test: (A) Commercial ointment group of damaged skin; (B) Commercial ointment group of complete skin; (C) Cubosomes of damaged skin; (D) Cubosomes of completed skin.
Figure 8The accumulated permeation studies of paeonol cubosome, commercial ointment and paeonol ordinary gel in SD rats.
The retention results of paeonol cubosomes and paeonol market ointment in skin and cuticle after 24 h (n=3).
| Samples | Epidermal/dermal (ug) | Cuticle (ug) |
|---|---|---|
| Paeonol cubosomes | 236.72±11.46 | 92.79±7.45 |
| Paeonol market ointment | 159.33±9.38 | 54.18±5.90 |
P<0.01.
Storage stability of paeonol cubosome (n=3).
| Group | Drug amount (μg/ml) | Particle size (nm) | Zeta potential (mv) | Encapsulation efficiency (%) | |
|---|---|---|---|---|---|
| Before experiment | 21.60±0.52 | 82.09±2.03 | −31.2±2.61 | 92.35 | |
| After experiment | 24 h | 21.54±0.36 | 82.61±1.37 | −30.5±0.96 | 91.76 |
| A month at −20°C | 16.13±0.55 | 83.56±3.95 | −35.7±3.64 | 90.02 | |
| A month at 2–8°C | 20.85±0.38 | 80.12±2.28 | −33.5±1.56 | 92.07 | |
| A month at room temperature | 21.27±0.19 | 82.19±1.33 | −32.1±1.87 | 92.15 | |